Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

AML-VAC-XS15-01: Multi-peptide vaccination adjuvanted with the TLR1/2 ligand XS15 in acute myeloid leukemia (AML) patients who have achieved… Recruiting

2023-510316-39-00 acute myeolic leukemia 1 2024-06-10
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
Phase II study: efficacy and safety of tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard chemotherapy Recruiting

2022-503090-11-00 Hodgkin lymphoma 4 2024-05-23
CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting

2023-505621-13-00 Richter´syndrome 4 2024-05-14
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting

2022-501648-14-00 Relapsed or refractory CD19 positive B cell malignancie 9 2024-05-05
Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting

2022-502276-23-00 JAK2V617F-positive high-risk Polycythemia Vera 5 2024-04-25
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with re… Recruiting

2023-508420-36-00 Relapsed/refractory B-cell Acute Lymphoblastic Leukemia 1 2024-04-23
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory… Recruiting

2023-508355-39-00 Relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leu 7 2024-04-20
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Acute myeloid leukemia 4 2024-04-07
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting

2022-501554-11-00 Patients with previously untreated Richter’s syndrome ( 4 2024-03-21
Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associate… Recruiting

2023-505933-29-00 IgM monoclonal gammopathy of unknown significance (MGUS 4 2024-03-13
Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting

2023-504146-60-00 lymphatic malformations associated with PIK3CA mutation 10 2024-02-07
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
Allogeneic CARCIK-CD19 in adults/pediatric B-cell Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia Recruiting

2023-505511-20-00 B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia 9 2024-01-29
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
Mitapivat in Membranopathies Recruiting

2023-503271-24-01 erythrocyte membranopathies 4 2023-12-29
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting

2022-502775-29-01 Early stage Follicular Lymphoma 5 2023-12-14
Prophylaxis Study of Marstacimab in Pediatric Hemophilia Participants With or Without Inhibitors Recruiting

2022-500495-65-00 Haemophilia 5 2023-12-06
Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy… Recruiting

2023-509793-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 4 2023-11-24
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting

2022-501869-41-00 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 9 2023-11-14
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting

2022-500453-16-00 Multiple Myeloma 4 2023-10-30
Phase II study of (early) combination salvage therapy with Venetoclax and intensified Decitabine in Relapsed/Refractory AML Recruiting

2022-502665-15-00 acute myeloid leukemia (AML) 4 2023-10-26
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate … Recruiting

2023-503906-35-00 Severe or Moderate Hemophilia A with or without factor 9 2023-10-11
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting

2023-510541-25-00 Relapsed/Refractory B-cell Malignancies 1 2023-10-09